Business Context and Reporting Period
Company: Brand Engagement Network Inc. (BNAI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2026 (Event Date: June 8, 2026)
Context: The Company entered into definitive agreements to establish INTERVENT Health AI, Inc., a 50/50 joint venture with INTERVENT International, LLC. The venture aims to develop and commercialize AI-powered health coaching solutions by combining BEN's conversational AI with INTERVENT's clinical health coaching methodologies and datasets.
Key Financial Metrics
This filing reports a strategic corporate action and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The filing text does not provide a clear value for current liquidity or operating margins.
Material Changes and Transaction Terms
- Joint Venture Structure: INTERVENT Health AI is capitalized with 100,000,000 shares of Class A Common Stock and 10,000,000 shares of Class B Preferred Stock.
- Ownership: BEN and INTERVENT each hold 32,500,000 shares of Class A Common Stock (50% each). An additional 30,000,000 Class A shares are reserved for future issuance, and 5,000,000 for a long-term incentive plan.
- Preferred Stock Consideration: Each party received 5,000,000 shares of Class B Preferred Stock, valued at $1.00 per share, as consideration for pre-paid intellectual property licenses.
- Revenue Sharing (North America): BEN (via subsidiary SKYE AI USA, LLC) is the exclusive provider of AI platform services for five years. BEN is entitled to 35% of certain revenues generated by the JV from software and services, net of commissions and third-party fees.
- Revenue Sharing (International): Proposed non-exclusive reseller arrangements in Latin America and Africa will allow INTERVENT Health AI to receive 50% of gross revenues from such sales after agreed commissions and expenses.
- Governance: The Board of Directors will consist of one BEN-appointed director, one INTERVENT-appointed director, and one independent director.
Outlook, Risks, and Management Commentary
Strategic Outlook: The JV intends to leverage BEN's AI technology and INTERVENT's proprietary assets, including clinical research datasets and telehealth coaching interactions with over 2,000,000 people, to target direct-to-consumer, employer, healthcare, and enterprise markets.
Contingencies: The North American commercialization arrangement is subject to agreed performance milestones. International reseller arrangements are proposed and subject to the terms of applicable agreements.
Risks: The filing notes customary ownership protection provisions, including restrictions on issuances that would reduce either founding shareholder below specified thresholds without approval.
Key Facts for Investor Verification
- Verify the specific performance milestones required to maintain the exclusive North American commercialization rights.
- Confirm the valuation methodology for the Class B Preferred Stock and the impact of the pre-paid license consideration on future financial statements.
- Review the full text of the Founding Shareholders Agreement (Exhibit 10.1) for detailed governance rights and exit provisions.
- Assess the timeline for the execution of the proposed international reseller agreements in Latin America and Africa.